Register Now - Every Drop Matters: Reducing Product Loss in Sterile Filtration
|Articles|January 17, 2014

Novasep Appoints New President of Synthesis Business Unit

Novasep selects Thierry van Nieuwenhove as new president of the synthesis business unit.

Novasep, a supplier of manufacturing solutions to the life sciences industry, has appointed Thierry van Nieuwenhove as president of the synthesis business unit.
Van Nieuwenhove holds a Master's degree in chemistry and biochemistry from the Catholic University of Louvain, Belgium. Van Nieuwenhove joins Novasep from Ajinomoto-Omnichem, a European synthetic molecules custom manufacturing organization, where he held positions as director, general manager, and member of the board.

Source: Novasep


Related to this article

The BioPharm Brief: A First for Streamlined Biosimilar Approval, a Head-to-Head Bispecific Trial in Wet AMD, and In Vivo KIR-CAR T
Biocon’s pertuzumab biosimilar Pebrilzo becomes the first biosimilar approved under EMA’s tailored clinical approach, Visara doses the first patient in a phase 2b trial comparing its VEGF-A/ANG-2 bispecific VIS-101 with aflibercept in wet AMD, and Verismo Therapeutics licenses Stanford’s PACK-IT technology for in vivo KIR-CAR T therapies.
Close-up of a clear IV infusion bag filled with pale yellow fluid, with a pink awareness ribbon printed on its front, against a gray background. | Image Credit: © Olga - stock.adobe.com
The European Commission has authorized Biocon’s pertuzumab biosimilar Pebrilzo as a HER2-positive breast cancer treatment, the first biosimilar cleared under EMA’s tailored clinical approach, which relies on analytical and pharmacokinetic data in place of a comparative efficacy trial. The EU biosimilar approval follows FDA approval of Pebrilzo two days earlier.